Shannon Westin, MD
Open to Accrual
Gynecologic [GY]
Multiple
II
No
RAS pathway mutations as determined by the ComboMATCH screening assessment. Measurable and biopsiable disease as defined by RECIST 1.1. Patients must have progressed after first-line treatment for recurrent or persistent disease. Patients with ovarian cancer should not be eligible for further platinum-based therapy. Patients with endometrial cancer must have received or been offered an immune oncology agent (alone or in combination with lenvatinib) unless there are existing contraindications for immune oncology agents or lenvatinib. Patients may have received unlimited prior therapy.
165
We are a leading protocol organizations within the National Clinical Trials Network and we seek to improve the lives of cancer patients by conducting practice-changing, multi-institutional clinical and translational research. Learn More
NRG Oncology Foundation, Inc, is a nonprofit, tax-exempt foundation. Donations to NRG Oncology help us conduct this important mission, and are tax-deductible to the extent permitted by law.